Preexisting diabetes, metformin use and long-term survival in patients with prostate cancer

References

• Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33(7):1674–1685.
   PubMed Web of Science ®Google Scholar
• Onitilo AA, Engel JM, Glurich I, et al. Diabetes and cancer I: risk, survival, and implications for screening. Cancer Causes Control. 2012;23(6):967–981.
   PubMed Web of Science ®Google Scholar
• Barone BB, Yeh HC, Snyder CF, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 2008;300(23):2754–2764. Dec 17
   PubMed Web of Science ®Google Scholar
• Chen Y, Wu F, Saito E, et al. Association between type 2 diabetes and risk of cancer mortality: a pooled analysis of over 771,000 individuals in the Asia Cohort Consortium. Diabetologia. 2017;60(6):1022–1032.
   PubMed Web of Science ®Google Scholar
• Sciacca L, Vigneri R, Tumminia A, et al. Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients. Nutr Metab Cardiovasc Dis. 2013;23(9):808–815.
   PubMed Web of Science ®Google Scholar
• Jian Gang P, Mo L, Lu Y, et al. Diabetes mellitus and the risk of prostate cancer: an update and cumulative meta-analysis. Endocr Res. 2015;40(1):54–61.
   PubMed Web of Science ®Google Scholar
• Bansal D, Bhansali A, Kapil G, et al. Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis. 2013;16(2):151–158.
   PubMed Web of Science ®Google Scholar
• Bensimon L, Yin H, Suissa S, et al. Type 2 diabetes and the risk of mortality among patients with prostate cancer. Cancer Causes Control. 2014;25(3):329–338.
   PubMed Web of Science ®Google Scholar
• Liu X, Ji J, Sundquist K, et al. The impact of type 2 diabetes mellitus on cancer-specific survival: a follow-up study in Sweden. Cancer. 2012;118(5):1353–1361.
   PubMed Web of Science ®Google Scholar
• D’Amico AV, Braccioforte MH, Moran BJ, et al. Causes of death in men with prevalent diabetes and newly diagnosed high- versus favorable-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2010;77(5):1329–1337.
   PubMed Web of Science ®Google Scholar
• Batty GD, Kivimaki M, Clarke R, et al. Modifiable risk factors for prostate cancer mortality in London: forty years of follow-up in the Whitehall study. Cancer Causes Control. 2011;22(2):311–318.
   PubMed Web of Science ®Google Scholar
• Chiou WK, Hwang JS, Hsu KH, et al. Diabetes mellitus increased mortality rates more in gender-specific than in nongender-specific cancer patients: a retrospective study of 149,491 patients. Exp Diabetes Res. 2012;2012:701643.
   PubMedGoogle Scholar
• Smith MR, Bae K, Efstathiou JA, et al. Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02. J Cin Oncol. 2008;26(26):4333–4339.
   PubMed Web of Science ®Google Scholar
• Lee J, Giovannucci E, Jeon JY. Diabetes and mortality in patients with prostate cancer: a meta-analysis. Springerplus. 2016;5(1):1548.
   PubMedGoogle Scholar
• American Diabetes Associaton. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S90–S102.
   PubMedGoogle Scholar
• Sui X, Xu Y, Wang X, et al. Metformin: a novel but controversial drug in cancer prevention and treatment. Mol Pharm. 2015;12(11):3783–3791.
   PubMedGoogle Scholar
• Spratt DE, Zhang C, Zumsteg ZS, et al. Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol. 2013;63(4):709–716.
   PubMed Web of Science ®Google Scholar
• Margel D, Urbach DR, Lipscombe LL, et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol. 2013;31(25):3069–3075.
   PubMed Web of Science ®Google Scholar
• He XX, Tu SM, Lee MH, et al. Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol. 2011;22(12):2640–2645.
   PubMed Web of Science ®Google Scholar
• Kaushik D, Karnes RJ, Eisenberg MS, et al. Effect of metformin on prostate cancer outcomes after radical prostatectomy. Urol Oncol. 2014;32(1):43 e1.
   PubMed Web of Science ®Google Scholar
• Bensimon L, Yin H, Suissa S, et al. The use of metformin in patients with prostate cancer and the risk of death. Cancer Epidemiol Biomarkers Prev. 2014;23(10):2111–2118.
   PubMed Web of Science ®Google Scholar
• Currie CJ, Poole CD, Jenkins-Jones S, et al. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care. 2012;35(2):299–304.
   PubMed Web of Science ®Google Scholar
• Raval AD, Thakker D, Vyas A, et al. Impact of metformin on clinical outcomes among men with prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2015;18(2):110–121.
   PubMed Web of Science ®Google Scholar
• Stopsack KH, Ziehr DR, Rider JR, et al. Metformin and prostate cancer mortality: a meta-analysis. Cancer Causes Control. 2016;27(1):105–113.
   PubMed Web of Science ®Google Scholar
• He K, Hu H, Ye S, et al. The effect of metformin therapy on incidence and prognosis in prostate cancer: a systematic review and meta-analysis. Sci Rep. 2019;9(1):2218.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Laversanne M, et al. Cancer incidence in five continents: inclusion criteria, highlights from Volume X and the global status of cancer registration. Int J Cancer. 2015;137(9):2060–2071.
   PubMed Web of Science ®Google Scholar
• Gurevicius R. An international assessment of the state and possibilities of Lithuanian health statistics. Visuomenes sveikata. 2019;2(85):7.
   Google Scholar
• Comstock CE, Revelo MP, Buncher CR, et al. Impact of differential cyclin D1 expression and localisation in prostate cancer. Br J Cancer. 2007;96(6):970–979.
   PubMed Web of Science ®Google Scholar
• Ben Sahra I, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008;27(25):3576–3586.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu G, Tong D, et al. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor. Prostate. 2015;75(11):1187–1196.
   PubMed Web of Science ®Google Scholar
• Dowling RJ, Zakikhani M, Fantus IG, et al. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007;67(22):10804–10812.
   PubMed Web of Science ®Google Scholar
• Mayer MJ, Klotz LH, Venkateswaran V. The effect of metformin use during docetaxel chemotherapy on prostate cancer specific and overall survival of diabetic patients with castration resistant prostate cancer. J Urol. 2017;197(4):1068–1075.
   PubMed Web of Science ®Google Scholar
• Zaorsky NG, Shaikh T, Ruth K, et al. Prostate cancer patients with unmanaged diabetes or receiving insulin experience inferior outcomes and toxicities after treatment with radiation therapy. Clin Genitourin Cancer. 2017;15(2):326–335 e3.
   PubMed Web of Science ®Google Scholar
• Taussky D, Preisser F, Karakiewicz PI, et al. Impact of diabetes and metformin use on prostate cancer outcome of patients treated with radiation therapy: results from a large institutional database. Can J Urol. 2018;25(5):9509–9515.
   PubMed Web of Science ®Google Scholar
• Richards KA, Liou JI, Cryns VL, et al. Metformin use is associated with improved survival for patients with advanced prostate cancer on androgen deprivation therapy. J Urol. 2018;200(6):1256–1263.
   PubMed Web of Science ®Google Scholar
• Chong RW, Vasudevan V, Zuber J, et al. Metformin has a positive therapeutic effect on prostate cancer in patients with type 2 diabetes mellitus. Am J Med Sci. 2016;351(4):416–419.
   PubMed Web of Science ®Google Scholar
• Joentausta RM, Kujala PM, Visakorpi T, et al. Tumor features and survival after radical prostatectomy among antidiabetic drug users. Prostate Cancer Prostatic Dis. 2016;19(4):367–373.
   PubMed Web of Science ®Google Scholar
• Xu H, Aldrich MC, Chen Q, et al. Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality. J Am Med Inform Assoc. 2015;22(1):179–191.
   PubMed Web of Science ®Google Scholar
• Randazzo M, Beatrice J, Huber A, et al. Influence of metformin use on PSA values, free-to-total PSA, prostate cancer incidence and grade and overall survival in a prospective screening trial (ERSPC Aarau). World J Urol. 2015;33(8):1189–1196.
   PubMed Web of Science ®Google Scholar
• Taira AV, Merrick GS, Galbreath RW, et al. Metformin is not associated with improved biochemical free survival or cause-specific survival in men with prostate cancer treated with permanent interstitial brachytherapy. J Contemp Brachyther. 2014;6(3):254–261.
   PubMed Web of Science ®Google Scholar
• Lu-Yao GL, Lin Y, Moore D, et al. Combination statin/metformin and prostate cancer specific mortality: a population-based study. J Cin Oncol. 2015;33(15_suppl):5018–5018.
   Web of Science ®Google Scholar
• Jarrard DF, Chen Y-H, Liu G, et al. Impact of metformin on prostate cancer (PC) outcomes in the E3805 CHAARTED trial. J Cin Oncol. 2017;35(6_suppl):181–181.
   Web of Science ®Google Scholar
• Gillessen S, Gilson C, James N, et al. Repurposing metformin as therapy for prostate cancer within the STAMPEDE trial platform. Eur Urol. 2016;70(6):906–908.
   PubMed Web of Science ®Google Scholar